- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Biovail buys Canada rights to Aczone
Biovail Laboratories, a subsidiary of Valeant Pharmaceuticals International, based here, has secured the Canadian distribution rights to Aczone, an acne treatment medication owned by Allergan, according news reports.
Mississauga, Ontario - Biovail Laboratories, a subsidiary of Valeant Pharmaceuticals International, based here, has secured the Canadian distribution rights to Aczone, an acne treatment medication owned by Allergan, according news reports.
CanadianBusiness.com quotes Valeant President and CEO Michael Pearson as saying, “Aczone gel is a strong addition to our Canadian business. This compound was originally approved in 2006 and never launched into the Canadian marketplace.”
The agreement calls for Allergan, based in Irvine, Calif., to receive a $500,000 initial payment as well as payments based on future sales.
